“The closure of this financing round and the successful recruitment of 545 patients in our first clinical study at the University Hospital Basel this year is a huge success”, states Marija Plodinec, CEO of ARTIDIS. “We are thankful for the support and trust of all our shareholders – together, we are opening a new chapter towards personalizing the patient journey.”
The funding will be used to advance the company’s healthtech platform into a large multi-centre clinical study together with the University Hospital Tuebingen, Germany, University Hospital Barcelona, Spain, and Texas Medical Center, Houston, US. The study aims to further providing further validate the value ARTIDIS in diagnosing breast and lung cancer, as well as for personalizing and optimizing cancer treatment. The results will support the regulatory submissions to the FDA and the European Notified Body to gain approval for the ARTIDIS medical device and data platform. This is one of the major prerequisites for ARTIDIS to enter the diagnostic market world-wide in 2021 in order to improve the standard of care for cancer patients.
ARTIDIS AG is a spin off from the lab of Argovia Prof. Roderick Lim at the Biozentrum and the Swiss Nanoscience Institute, University of Basel. The startup has developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. ARTIDIS’ nanotechnology platform integrates different types of clinical data, allowing physicians to significantly shorten the current diagnostic process to benefit both the patient and the healthcare system. ARTIDIS enables professionals to design personalized cancer treatment plans tailored to the individual patient needs and desired outcomes.